secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aura Biosciences, Inc. (AURA)
CIK:        0001501796
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021284
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aura Biosciences reports Q1 2023 net loss of $17.5M; FDA backs Phase 3 trial design for choroidal melanoma
--------------------------------------------------------------------------------

- Cash and marketable securities $173.5M as of March 31, 2023; cash runway into 2025.
- Net loss $17.5M for Q1 2023 vs $12.8M in Q1 2022; R&D expense $14.4M (up from $8.3M).
- FDA Type C meeting supports global Phase 3 trial (≈100 patients, 2:1:2 randomized) for early-stage choroidal melanoma.
- Phase 2 enrollment complete; updated interim data expected 2H 2023; Phase 1 NMIBC data also due 2H 2023.
- Appointed Patrick Nealon as SVP, Clinical Development Operations to lead late-stage development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/0000950170-23-021284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501796/000095017023021284/aura-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer